Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
| Autor: | Rachid Jlidi, Boutheina Cherif, N Ben Yahia, Ahmed Rebai, H. Ayadi, E-Z Ayadi, Mourad Mokni, Y Ben Hamed |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Adult medicine.medical_specialty BCL2 Lymphoma B-Cell Adolescent Receptor ErbB-2 Breast Neoplasms 03 medical and health sciences Young Adult 0302 clinical medicine Breast cancer Internal medicine Immunochemistry Biomarkers Tumor Medicine Humans B-cell lymphoma Lymph node Grading (tumors) Triple-negative breast cancer Retrospective Studies young women business.industry Carcinoma Ductal Breast General Medicine medicine.disease Prognosis Pathophysiology 030104 developmental biology medicine.anatomical_structure Ki-67 Antigen Proto-Oncogene Proteins c-bcl-2 Receptors Estrogen 030220 oncology & carcinogenesis Cohort Female Tumor Suppressor Protein p53 business Research Article |
| Zdroj: | Asian Pacific Journal of Cancer Prevention : APJCP |
| ISSN: | 2476-762X 1513-7368 |
| Popis: | Background: Breast cancers are heterogeneous, making it essential to recognize several biomarkers for cancer outcome predictions especially in young women where the classical prediction parameters are not suitable. The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival in young women patients with invasive ductal carcinoma. Patients and methods: Samples and clinical data from 238 patients were collected between 2003 and 2017. They were selected according to 2 criteria: age ≤40 years old and most of them are affected by an Invasive Ductal Carcinoma. We evaluated BCL2, P53 and ki-67 expression by immunochemistry test, and then we assessed correlations of these biomarkers expression with patient’s clinicopathological characteristics and survival. Results: Triple negative breast cancer group showed a high frequency among our cohort but we emphasize an almost equitable distribution among all molecular groups. Contrary to other studies which reported that luminal A was correlated with better prognosis, our analysis demonstrated that luminal A is correlated with the Scarff, Bloom and Richardson (SBR) grading 2 or SBR grading 3. To better investigate the prognosis, we analyze three biomarkers known by their impact on physiopathology behavior on breast cancer BCL2, ki-67and P53. BCL2 is the more relevant one, it was correlated with molecular subtypes (p=0.0012) and SBR grading (p=0.0016). BCL2 seems to be the good prognostic biomarker related to survival (p=0.004) with a protective role among patients when endocrine therapy is not provided and Lymph Node (LN) involvement is positive (p=0.021, p=0.000 respectively). Conclusions: The classical prognostic parameters based mainly on the molecular classification in breast cancer seem insufficient in the case of young women. BCL2 protein expression analysis provides a better prognostic value. BCL2 should be clinically associated in current practice when young women specimens are diagnosticated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|